Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
The role of GPCRs and homing molecules in the control and regionalization of mucosal immunity. (GREMLIN)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Immunity, Infection and I mmunotherapy
Panel description: The immune system , related disorders  and their mechanisms , biology of infectious agents and infection, biological basis of prevention and treatment of infectious diseases , innovative imm unological tools and approaches , including  therapies
Countries involved: Italy
Call: ERC STARTING GRANTS (ERC-2023-STG, 2023)
Start date: 2024-01-01
End date: 2028-12-31
Duration (months): 60.0
Total project cost (EUR): 1500000.0
EU funding (EUR): 1500000.0
Participants: 1
Project status: SIGNED

Mucosal immunity is essential to preserve homeostasis and for pathogen control within the gut and the airways. The emerging dogma of immune regionalization has opened to new questions about which elements drive cell adaptation to different niches, and how this can be targeted to cure diseases. The intestine and the airways are functionally diverse along their length, and disorders can differentially impact on different mucosal tissue regions. Mucosa-associated lymphoid tissues (MALTs) are located along the intestine and the airways to drain selective tissue segments and support protective immunity. Whether MALTs located in different tissue areas show immune regionalization remains poorly understood. Also, little is known about which molecules control such immune diversity. G protein-coupled receptors (GPCRs) are surface proteins important for cell migration and compartmentalization in lymphoid tissues, but their role in immune regionalization is not clear. We propose to apply a combination of imaging, flow cytometry, spatial gene editing and sequencing techniques to study the role of GPCRs in immune regionalization of MALTs, at steady state and in disease. In the intestine, we will phenotypically and functionally profile immune cells and GPCRs expression within Peyer's patches (PPs) from different gut regions, in physiology or in the context of inflammation and obesity. Similarly, we will analyze immune regionalization of bronchus-associated lymphoid tissues and nose-associated lymphoid tissues within the airways, at steady state or upon infections. Finally, we will characterize the role of a candidate GPCR, GPR35, in the induction of intestinal and respiratory immunity. Our preliminary data show that GPR35 shapes cell recruitment to inflamed airways and influences cell positioning within PPs. By applying the above-mentioned approaches and dedicated mouse models, we will study how GPR35 regulates mucosal immunity and if it represents an attractive clinical target.

Keywords: gpcrs cell migration myeloid cell intestinal immunity airways infections
PLASTicity of Endothelial Cell as new Target for acute myeloId leukemia TherapY (PLASTECITY)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Physiology in Health, Disease and Ageing
Panel description: Organ and tissue physiology, comparative physiology, physiology  of ageing , pathophysiology, inter - organ and tissue communication, endocrinology, nutrition,  metabolism, interaction with the microbiome, non -communicable diseases including cancer (and except disorders of the nervous system  and immunity -related diseases)
Countries involved: France
Call: ERC STARTING GRANTS (ERC-2023-STG, 2023)
Start date: 2024-07-01
End date: 2029-06-30
Duration (months): 60.0
Total project cost (EUR): 1499000.0
EU funding (EUR): 1499000.0
Participants: 1
Project status: SIGNED

Acute myeloid leukemias (AML) are aggressive blood cancers with poor overall prognosis. The main intervention line is high-dose chemotherapy, often associated with resistance, relapse and long-term side effects. Although predominantly considered as genetic diseases of the hematopoietic system, AML also affect the bone marrow (BM) microenvironment, which contributes to disease pathogenesis. Particularly, we have revealed a thorough remodeling of the vascular tree, with endothelial cells (ECs) displaying dismantled junctions and an embryonic-like molecular signature. Our research hypothesis is that this embryonic-like ECs (E-ECs)– displaying a high grade of plasticity – are progressively enriched during AML progression and foster a leukemia-reinforcing environment. Thus, this proposal aims at (1) deciphering the nature of enriched E-ECs in AML pathogenesis and (2) identifying effective strategies to target them to improve therapeutic response. To this end, we will combine in vivo lineage tracing and OMIC studies in consolidated transplantable models of AML and patient-derived samples to decipher the molecular and clonal dynamics of BM ECs as well as their phenotypic plasticity toward regained Endothelial-to-Hematopoietic and Endothelial-to-Mesenchymal transition potential. We will next explore novel therapeutic avenues by targeting microenvironmental plasticity in AML via candidate genes associated with the aforementioned phenotypes in vivo with engineered CRISPR-nanobodies. Finally, this knowledge will be translated to the human system via pre-clinical validation of putative targets in a state-of-the-art human vascularized BM-on-chip platform. In conclusion, this research proposal will uncover essential molecular mechanisms regulating stem cell niche dynamics in normal and pathological conditions, provide a thorough understanding of the molecular and cellular plasticity of BM ECs and will result in innovative strategies to ameliorate AML clinical treatments.

Keywords: vascular system tumor microenvironment genetic engineering stem cells
The Roots of Civility. French Renaissance literature as a laboratory of modern civility (CIVILITY)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: France
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2023-07-10
End date: 2025-07-09
Duration (months): 24.0
Total project cost (EUR): 211754.88
EU funding (EUR): 211754.88
Participants: 1
Project status: CLOSED

Renaissance men and women had a passion for virtue and a genius for cruelty. They had wonderful manners and barbaric inclinations, lovely clothes and terrible diseases. Can they really teach us something about civility? I think they can: they were made of contradictions and so are we. And both, we and they, dream of a society where politeness and respect reduce tensions and allow a peaceful and pleasant cohabitation for all. The goal of this research project, executed at the University of Lille under the supervision of Marie-Claire Thomine, is to prove that the roots of civility go back to the 16th century and that there was a mature form of civility in the Renaissance France a century before what is usually considered to be the beginning of the 'politesse française'. I will identify its main models and situate them in relation to the previous (medieval) ones and those from the century of Louis XIV. I will argue that Renaissance authors used the literature as the principal means of wide diffusion of this new civility, and this is precisely what makes this century a turning point in the history of manners in France and a part of the cultural reform initiated by the kings and queens of France to build a more cohesive and peaceful society. Furthermore, I want also to prove that this evolution can be observed using the modern tools of historical pragmatics, a branch of pragmatics that had developed strongly over the last twenty years but was not yet used to study the phenomenon of (im)politeness in France during the Renaissance. I will accomplish those goals through a program of close reading of prose texts (essentially literary dialogues and collections of short stories) of the 15th and 16th centuries, informed by the literature of civility, and through corpus-based research to detect and define evolution in verbal and nonverbal behaviors in the time of the last kings of the Valois dynasty.

Keywords: french,renaissance,literature,civility,short stories,early modern,manners
Migrant Voices: Fighting Linguistic Discrimination from Spaces of Cultural and Artistic Production in Spain (MigrantVoices)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Spain
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2024-01-01
End date: 2025-12-31
Duration (months): 24.0
Total project cost (EUR): 165312.96
EU funding (EUR): 165312.96
Participants: 1
Project status: CLOSED

While linguistic diversity is promoted at the supranational level by the European Union policies, standardization and homogenization still prevail at the national level in most European countries in alignment with the one state - one language nationalistic ideology. In this context, any speaker who deviates from the standard norm, in particular, migrants and their descendants are often misrecognized as linguistically deficient. A discriminatory process that entails social, economic, and political consequences. The case of Spain is paradigmatic, given the attested pressure towards normativity in the dominant variety of Castilian Spanish, especially in monolingual regions like Madrid. Drawing on interdisciplinarity, this project, MigrantVoices, aims to address this issue and open paths for social transformation. The project will provide and analyze examples of instances in which migrant voices – usually unheard– have reached domains of public influence in society and have managed to challenge and transform the linguistic prejudices that affect them. These instances of speaking out against linguistic discrimination coming from migrant communities have been deeply analyzed in the US but have not yet been studied in the European context. To analyze these initiatives, this action proposes an innovative change in perspective by focusing on artistic and cultural spaces which influence social practices and beliefs, and which have yet to be explored. Drawing on ethnography and participatory methods, this project will provide an analyzed corpus of successful experiences. This will contribute to generating public knowledge on the possibilities to foster immigrants’ inclusion and participation in European societies, which is one of the EU’s political priorities for 2021-2027. In doing so, MigrantVoices will also raise awareness of the role of language in discriminative processes, and promote fairer individual, social and institutional approaches to language.

Keywords: linguistic discrimination migrants agency language and inequality raciolinguistics
Integration of heterogeneous Data and Evidence towards Regulatory and HTA Acceptance (IDERHA)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Public-private partnerships
Destination: Innovative Health Initiative
Action type: Research and Innovation actions
Partnership: IHI (JU-JTI)
Countries involved: Germany,Netherlands,Luxembourg,Belgium,Finland,Austria,Switzerland,Spain,Denmark,United Kingdom,France,United States
Call: Access and integration of heterogeneous health data for improved healthcare in disease areas of high unmet public health need (HORIZON-JU-IHI-2022-01-single-stage, 2022)
Start date: 2023-04-01
End date: 2028-03-31
Duration (months): 60.0
Total project cost (EUR): 36181150.86
EU funding (EUR): 23032209.61
Participants: 40
Project status: SIGNED

IDERHA will address the key obstacles to achieving appropriate access, sharing, use and reuse of lung cancer data, and thus enable enhanced regulatory and HTA decision-making recommendations for integrated health research, with the aim to improve care and better meet the needs of patients and health care professionals. The IDERHA open platform for multi-modal health data will enhance innovation in EU health care systems and is directly scalable by means of connecting additional systems, data sources and additional services and tools. It will extend and elaborate standards in semantic interpretation, data quality, ethics and transferability to ensure the harmonisation of heterogeneous data sources and wider health data reuse. Use cases positioned along the lung cancer patient pathway will be implemented using retrospective data and in a remote patient care context. These practical implementations will demonstrate the added value of multi-modal data aggregation and analysis with impacts expected on public health, patient burden, health outcomes and cost. We will perform AI/ML based lung-cancer risk profiling using patient`s EHRs, and improved CT image- based AI/ML to provide risk prediction of potential lung cancer patients, and explore the possibilility of personal prognosis of disease progression. Using patient monitoring and engagement, including digital biomarker, PROMs, and connected devices, the IDERHA platform will enable remote patient monitoring, and provide data for joint patient-health professional decision making. Along with health care stakeholders, IDERHA will develop consensus policy recommendations for appropriate data sharing to enable multi-stakeholder research. Informed by Patient Advisory Groups, we will address critical obstacles and issues to heterogeneous health data primary and secondary use. Regulatory and HTA agencies will be engaged to create criteria for assessing the acceptability of heterogeneous health research results in regulatory and HTA decision-making.

Keywords: lung cancer,regulatory decision making,data integration and application,continuum of care,patient engagement,rwe,ai ml,ehds,wearables,clinical decision support,eu policies,fair
How Adaptive Neural Dynamics Weight and Integrate Auditory and Visual Information during Multimodal Language Processing (HANDWAVE)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: The Human Mind and Its Compl exity
Panel description: Cognitive science, psychology, linguistics
Countries involved: Netherlands
Call: ERC STARTING GRANTS (ERC-2025-STG, 2025)
Start date: 2026-01-01
End date: 2030-12-31
Duration (months): 60.0
Total project cost (EUR): 1499980.0
EU funding (EUR): 1499980.0
Participants: 1
Project status: SIGNED

HANDWAVE will develop a novel framework for understanding the neurobiology of multimodal language, by uncovering the multi-timescale oscillatory mechanisms that enable the flexible integration and weighting of auditory signals, such as speech, and visual signals, such as visual speech and hand gestures. Understanding how the brain integrates and weights these signals is crucial for understanding how natural language is processed in the brain. This knowledge is vital for diagnosing and treating language-related disorders, and for developing effective diagnostic tools and rehabilitation strategies. Two key gaps remain unaddressed. First, historical models on the neurobiology of language have predominantly focused on unimodal speech signals, overlooking the inherently multimodal nature of language. Second, it is unknown how the complex temporal relations between auditory and visual signals allow them to be integrated into one coherent percept. HANDWAVE addresses these gaps by testing the central hypothesis that the brain’s flexible coordination of multi-timescale oscillations enables the integration and weighting of auditory and visual signals through (interactions between) phase modulations, power modulations, and functional connectivity. Work package (WP) 1 will uncover the oscillatory mechanisms underlying the integration of speech and visual signals, and whether and how this gives rise to emergent multimodal representations in the brain. WP2 will examine the oscillatory mechanisms underlying the flexible weighting of auditory and visual signals. WP3 will provide causal evidence for the role of oscillatory mechanisms in supporting integration and weighting. By uncovering the multi-timescale oscillatory mechanisms underlying these processes, HANDWAVE has the potential to redefine theoretical models of the neurobiology of language. Its findings will inspire clinical interventions and communication technologies that better capture the multimodal nature of language.

Keywords: gesture visual speech speech noise speech gesture integration multimodal language multimodal integration neural oscillations neurolinguistics
Organization and function of the axonal Endoplasmic Reticulum (synERgy)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Neuroscience and Disorders of the Nervous System
Panel description: Nervous system development, homeostasis and ageing , nervous system  function and dysfunction , systems neuroscience  and modelling , biological basis of cognitive processes and of behaviour, neurological and mental disorders – In humans and all other organisms
Countries involved: Netherlands
Call: ERC STARTING GRANTS (ERC-2021-STG, 2021)
Start date: 2022-07-01
End date: 2027-06-30
Duration (months): 60.0
Total project cost (EUR): 1500000.0
EU funding (EUR): 1500000.0
Participants: 1
Project status: SIGNED

Brain function relies on neurotransmission at synapses, where local increases in calcium trigger the fusion of synaptic vesicles and release of their neurotransmitters. Decades of research yielded detailed knowledge on synaptic vesicles and the individual proteins that mediate neurotransmission. Conversely, we know surprisingly little about the synaptic contribution of the largest organelle in neurons: the Endoplasmic Reticulum (ER). Aberrant alterations in ER shape are, however, associated with many neurologic disorders, highlighting the importance of understanding the role this organelle plays in the neuron. Taking into consideration the mere quantity and range of specialized ER functions such as calcium signalling and lipid synthesis, the neuronal ER has received very little attention. I therefore strive to shed light on the major, unresolved questions of the field, namely what the ER protein composition is in synapses and how the ER contributes to important neuronal functions such as neurotransmission. To dissect ER function in neurons I will first characterize the composition of neuronal ER proteins and identify the key players that regulate ER degradation. Second, I will manipulate ER content, localization and degradation to understand how the ER contributes to neurotransmission and development. Finally, I will investigate the importance of ER and ER degradation for physiological and pathophysiological processes in vivo. To this end, I propose a multidisciplinary approach using advanced imaging techniques, endogenous protein tagging and proteomics to study ER function and its regulated degradation in neurons. These studies will yield innovative fundamental insights into the role of synaptic ER and thereby fill a crucial knowledge gap in neuroscience. Furthermore, they will provide a better understanding and explanation of how defects in ER and ER degradation cause neurodegenerative diseases.
BIOmarker based diagnostic TOOLkit to personalize pharmacological approaches in congestive heart failure (BIOTOOL-CHF)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Unlocking the full potential of new tools, technologies and digital solutions for a healthy society
Action type: Research and Innovation actions
Countries involved: Italy,Netherlands,Sweden,France,Greece,Slovenia,Spain,Belgium,Denmark,Germany,Switzerland
Call: Optimising effectiveness in patients of existing prescription drugs for major diseases (except cancer) with the use of biomarkers (HORIZON-HLTH-2022-TOOL-11, 2022)
Start date: 2023-10-01
End date: 2028-09-30
Duration (months): 60.0
Total project cost (EUR): 9600663.0
EU funding (EUR): 9600663.0
Participants: 25
Project status: SIGNED

Heart failure (HF) is a chronic clinical condition involving up to 6.5 million people in Europe, the most frequent cause of hospitalization in adults with a 5-year mortality rate up to 70%. Several drugs positively modify the course of disease in the patients with HF with reduced ejection fraction (HFrEF), with a high level of evidence. Besides, the use of diuretics, the basic cornerstone of symptoms relief in HFrEF by targeting congestion, is supported by poor and outdated evidence. Congestion drives symptoms worsening leading to hospital admission. Clinical evaluation of congestion is often inaccurate and insensitive to detect interstitial or intravascular fluid overload, and thus insufficient to guide use of diuretics. Indeed, their use is inefficient, with studies showing that up to 70% of patients with chronic HFrEF show congestion despite diuretic therapy, the use of diuretics does prevent clinical events in patients discharged after an acute heart failure episode, and diuretics may represent a barrier to adherence to disease modifier therapies. An appropriate management of diuretic therapy is therefore crucial to overcome the risk of re-hospitalisation, manage patients symptoms, and achieve target guideline-directed medical therapy. To fill these gaps, BIOTOOL-CHF will 1) validate a set of qualified biomarkers estimating congestion, 2) define a multiparametric artificial intelligence-based score predicting congestion and prognosis, 3) develop a decision-making tool to manage congestion by diuretics, 4) develop a Point of Care companion diagnostic (CD) to assess biomarkers concentrations 5) set up a Strategy plan for industrial development and market access of the CD. This approach will support the definition of a framework to regulatory agencies and scientific societies to disseminate recommendations for a more efficient use of existing pharmaceuticals and allow a personalised strategy for the management of HFrEF, by using new tools and digital solutions.

Keywords: heart failure,personalized medicine,valued based medicine,biomarkers,artificial intelligence,companion diagnostic,decision making tool,quality of life,diuretics,congestion